1. Scheggia D, Mastrogiacomo R, Mereu M, Sannino S, Straub RE, Armando M, et al. Variations in Dysbindin-1 are associated with cognitive response to antipsychotic drug treatment. Nat Commun. 2018 Jun 11;9(1):2265.
2. Ibi D, de la Fuente Revenga M, Kezunovic N, et al. Antipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects. Nat Neurosci. 2017;20(9):1247-1259. doi:10.1038/nn.4616
3. Husa AP, Moilanen J, Murray GK, Marttila R, Haapea M, Rannikko I, et al. Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort. Psychiatry Res. 2017 Jan 1;247:130–8.
4. Cadena EJ, White DM, Kraguljac NV, Reid MA, Jindal R, Pixley RM, et al. Cognitive control network dysconnectivity and response to antipsychotic treatment in schizophrenia. Schizophr Res. 2019 Feb 1;204:262–70.
5. MacKenzie NE, Kowalchuk C, Agarwal SM, et al. Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia. Front Psychiatry. 2018;9:622. Published 2018 Dec 5. doi:10.3389/fpsyt.2018.00622
6. Stahl SM. Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes. CNS Spectr. 2017 Oct;22(5):375–84.
7. Rajagopal L, Kwon S, Huang M, Michael E, Bhat L, Cantillon M, et al. RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia. Behav Brain Res. 2017 Aug 14;332:180–99.
8. Nielsen RE, Levander S, Kjaersdam Telléus G, Jensen SO, Østergaard Christensen T, Leucht S. Second-generation antipsychotic effect on cognition in patients with schizophrenia--a meta-analysis of randomized clinical trials. Acta Psychiatr Scand. 2015;131(3):185-196. doi:10.1111/acps.12374.
9. Spagna A, Dong Y, Mackie M-A, Li M, Harvey PD, Tian Y, et al. Clozapine improves the orienting of attention in schizophrenia. Schizophr Res. 2015 Oct 1;168(1):285–91.
10. Trampush JW, Lencz T, DeRosse P, et al. Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders. Schizophr Bull. 2015;41(6):1237-1247. doi:10.1093/schbul/sbv120
11. Takeuchi H. Seishin Shinkeigaku Zasshi. 2015;117(7):562-567.
12. El-Missiry A, Elbatrawy A, El Missiry M, Moneim DA, Ali R, Essawy H. Comparing cognitive functions in medication adherent and non-adherent patients with schizophrenia. J Psychiatr Res. 2015 Nov 1;70:106–12.
13. Fagiolini A, Rocca P, De Giorgi S, Spina E, Amodeo G, Amore M. Clinical trial methodology to assess the efficacy/effectiveness of long-acting antipsychotics: Randomized controlled trials vs naturalistic studies. Psychiatry Res. 2017;247:257-264. doi:10.1016/j.psychres.2016.11.044
14. Fervaha G, Agid O, Takeuchi H, Lee J, Foussias G, Zakzanis KK, et al. Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia. Schizophr Res. 2015 Feb 1;161(2):351–6.
15. Galling B, Roldán A, Nielsen RE, et al. Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2016;73(3):247–259. doi:10.1001/jamapsychiatry.2015.2923
16. Kanji S, Fonseka TM, Marshe VS, Sriretnakumar V, Hahn MK, Müller DJ. The microbiome-gut-brain axis: implications for schizophrenia and antipsychotic induced weight gain. Eur Arch Psychiatry Clin Neurosci. 2018 Feb 1;268(1):3–15.
17. Raben AT, Marshe VS, Chintoh A, Gorbovskaya I, Müller DJ, Hahn MK. The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment. Front Neurosci. 2018;11:741. Published 2018 Jan 22. doi:10.3389/fnins.2017.00741
18. Walker JM, Harrison FE. Shared Neuropathological Characteristics of Obesity, Type 2 Diabetes and Alzheimer's Disease: Impacts on Cognitive Decline. Nutrients. 2015;7(9):7332-7357. Published 2015 Sep 1. doi:10.3390/nu7095341